相关实验视频

Updated: Jun 13, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在非小细胞肺癌中免疫治疗后具有混合反应的渐进性疾病

Juncai Lv¹, Weiwei Yan¹, Ran Zhang¹

¹Department of Radiation Oncology and Shandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, People's Republic of China.

Journal of inflammation research

|September 16, 2024

概括

这项研究确定了免疫治疗期间非小细胞肺癌 (NSCLC) 患者的特定混合反应. 继续治疗这些患有混合反应进展性疾病 (PDMR) 的患者可以延长存活时间.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
辐射疗法辐射疗法

背景情况:

对非小细胞肺癌 (NSCLC) 患者进行的研究有限,患者在免疫疗法期间总体呈进展性疾病和缩小病变,这种现象称为混合反应.
了解这些患者的临床特征和治疗结果对于优化免疫治疗策略至关重要.

研究的目的:

评估在免疫治疗期间经历混合反应 (PDMR) 的进展性疾病的NSCLC患者的临床特征和治疗选择.
为了比较PDMR患者和非混合反应 (PDNMR) 患者之间的结果.

主要方法:

根据病变总体进展的反应,患者被分为PDMR (n=31) 和PDNMR (n=144) 组.
用CT扫描和MRI进行评估,然后进行多变量分析以确定预后因素.

主要成果:

在PDMR患者中,病期较差,前期放射治疗率较高.
与PDNMR相比,PDMR组的总生存时间 (mOS) 和无进展生存时间 (mPFS) 的中位数显著较短.
在PDMR后继续免疫治疗显著改善了随后的整体存活率 (mOS 23.9 vs 6.5 个月).

结论:

具有混合反应的进展性疾病 (PDMR) 在第四阶段和先前照射过NSCLC的患者中更为常见.
与PDNMR患者相比,PDMR患者的整体存活率和无进展存活率较低.
在PDMR患者中,持续免疫治疗可以延长存活时间,突出显示出一种潜在的治疗策略.

关键词:

免疫疗法免疫疗法这是一种混合反应.非小细胞肺癌的肺癌.这是一个渐进的过程.

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...